William Blair Issues Pessimistic Forecast for KROS Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at William Blair dropped their FY2024 earnings estimates for Keros Therapeutics in a research note issued to investors on Wednesday, November 6th. William Blair analyst M. Phipps now expects that the company will post earnings of ($5.17) per share for the year, down from their prior forecast of ($5.00). The consensus estimate for Keros Therapeutics' current full-year earnings is ($5.14) per share. William Blair also issued estimates for Keros Therapeutics' Q4 2024 earnings at ($1.30) EPS, Q1 2025 earnings at ($1.23) EPS, Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($4.16) EPS, FY2026 earnings at ($3.47) EPS and FY2027 earnings at ($3.15) EPS.

Several other analysts also recently issued reports on KROS. Jefferies Financial Group started coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a "buy" rating for the company. Wedbush reissued an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday. HC Wainwright reiterated a "buy" rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday. Scotiabank began coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on Keros Therapeutics in a research note on Thursday, October 24th. They issued an "overweight" rating for the company. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $88.89.

Keros Therapeutics Trading Up 0.4 %

Shares of NASDAQ:KROS traded up $0.24 during trading on Monday, reaching $68.15. 422,580 shares of the stock were exchanged, compared to its average volume of 370,804. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00. The stock has a 50-day moving average price of $58.19 and a 200-day moving average price of $52.13. The firm has a market cap of $2.56 billion, a PE ratio of -13.08 and a beta of 1.23.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The business's revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period last year, the firm earned ($1.33) earnings per share.

Institutional Investors Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. KBC Group NV raised its position in Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company's stock valued at $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in Keros Therapeutics by 26.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after acquiring an additional 280 shares during the last quarter. Values First Advisors Inc. acquired a new position in Keros Therapeutics in the 3rd quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the 2nd quarter valued at approximately $128,000. Finally, Ameritas Investment Partners Inc. lifted its holdings in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company's stock worth $169,000 after purchasing an additional 324 shares during the period. Institutional investors own 71.56% of the company's stock.

Insider Activity

In related news, Director Carl L. Gordon sold 250,000 shares of the firm's stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total value of $11,002,500.00. Following the sale, the director now directly owns 119,522 shares of the company's stock, valued at $5,260,163.22. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 22.90% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.